Table 1.

In vivo tumorigenicity of manipulated HBECs

Cell lineMediumaTumor formation ratebLatency, dcHistology
HBEC3 p53,KRAS
 PopulationKSFM5/24 (21%)152SCC (2) Adenosquamous (2)Poorly differentiated carcinoma (1)
 PopulationR107/17 (41%)128Large cell/giant cell carcinoma (3)Adenocarcinoma (2)SCC (1)Adenosquamous (1)
 Clone 1R108/8 (100%)38Large cell/giant cell carcinoma (7)SCC (1)
 Clone 5R107/8 (88%)57Large cell/giant cell carcinoma (5)Papillary adenocarcinoma (1)Poorly differentiated carcinoma (1)
 Clone 11R106/8 (75%)117Large cell/giant cell carcinoma (3)Poorly differentiated carcinoma (2)Adenocarcinoma (1)
 Clone 6R100/6 (0%)
 Clone 7R100/7 (0%)
 Clone 8R100/8 (0%)
 Clone 9R100/9 (0%)
HBEC3 p53,KRAS,MYC
 PopulationKSFM3/10 (30%)115Adenosquamous (2)SCC (1)
 PopulationR1012/12 (100%)27Large cell/giant cell carcinoma (5)Poorly differentiated carcinoma (4)SCC (2)
 Clone 1R109/9 (100%)119Large cell/giant cell carcinoma (7)Adenocarcinoma (2)
 Clone 2R103/8 (38%)90SCC (2) Large cell/giant cell carcinoma (1)
 Clone 7R1010/10 (100%)37Large cell/giant cell carcinoma (7)SCC (3)
 Clone 8R101/6 (17%)78Large cell/giant cell carcinoma (1)
HBEC17 p53,KRAS
 PopulationKSFM0/9 (0%)
 PopulationR100/8 (0%)
HBEC17 p53,KRAS,MYC
 PopulationKSFM0/10 (0%)
 PopulationR103/8 (38%)n.d.SCC (2)Sarcomatoid carcinoma features (1)
  • aR10, RPMI-1640 supplemented with 10% FBS.

  • bNumber of subcutaneous tumors/number of injections (%).

  • cMedian time (days) for subcutaneous xenografts to reach 250 mm3; n.d., not determined.